Medtronic has announced promising results from studies on the MiniMed 780G system for individuals with type 2 diabetes and young children with type 1 diabetes. The data, presented at the American Diabetes Association’s 85th Scientific Sessions in Chicago, shows improved glycemic outcomes for those using the system under investigational use.
Participants in a clinical trial of individuals with insulin-intensive type 2 diabetes achieved an average increase of 8.6% in Time in Range (TIR), reaching 84.9%, surpassing the ADA goal of 70%. Additionally, there was a reduction in HbA1C from 7.7% to 6.9%, meeting ADA targets for diabetes management.
The LENNY trial results, published in The Lancet Diabetes & Endocrinology, evaluated the MiniMed 780G system in young children aged 2-6 years with type 1 diabetes. Children using the system with SmartGuard showed a lower HbA1C by 0.6% and a higher TIR by 9.9% compared to baseline therapy without autocorrections. Parents reported improved sleep quality and reduced fear of hypoglycemia when using auto mode.
Dr. Robert Vigersky, Chief Medical Officer at Medtronic Diabetes, stated: “As the industry moves toward broader indications of automated insulin delivery systems, we see tremendous potential to improve outcomes and quality of life for millions of people managing type 2 diabetes with insulin.”
Prof. Tadej Battelino highlighted the importance of maintaining healthy blood glucose levels from early disease onset to preserve brain development and minimize long-term complications: “We are hopeful that if the data continues to be strong, the MiniMed 780G system can help make this possible.”
The MiniMed 780G system is not yet approved for use in type 2 diabetes or young children under seven by regulatory bodies such as the U.S. FDA. However, Medtronic plans to work towards expanding access to its technology for these groups.
Prof. Ohad Cohen expressed optimism about future indication expansion: “We’re hopeful that if the data continues to be strong, we will receive future indication expansion so the most vulnerable group…can also benefit from this technology.”
###
